Asia Pacific Renal Biomarkers Market

Asia Pacific Renal Biomarkers Market Size & Growth (2022 to 2027):

The Size of the Asia Pacific Renal Biomarkers Market was valued at USD 247.08 million in 2022 and estimated to grow at a CAGR of 9.24%, to reach USD 384.42 million by 2027 during the forecast period 2022 to 2027.

The increased incidence of numerous kidney-related disorders, the high prevalence of diabetes and high blood pressure, which are the primary causes of renal diseases, and rapid technological advancements in genetics, are driving the expansion of this market in the Asia Pacific. In addition, because of developments in computer technology, renal biomarker testing is now widely available and possible, even in small laboratories. 

Recent genetic findings have enabled researchers to utilize several platforms to study kidney disease in human populations. Renal biomarkers can also be used in genetic-level technological advancements to detect, diagnose, and treat kidney disease. Genetics analyses have become indispensable in clinical practice and research due to significant improvements in genomic technologies. 

The industry would also gain traction as more people develop chronic conditions like diabetes, obesity, and hypertension, linked to the slow loss of kidney function. However, they are time demanding and lack sensitivity and specificity. With the advancement of genomics, proteomics, transcriptomics, and metabolomics, novel diagnostic tools such as renal biomarkers should be willing to help in the early diagnosis of renal disorders.

The biomarker's expansion is projected to be hampered by a lack of validated innovative renal biomarkers and their failure to correlate with clinical outcomes. Most kidney biomarkers peak too late, making it difficult to link them to biological or clinical results. Today's renal biomarkers are more predictive of renal function than renal injury. 

They are influenced by non-renal factors, including gender, age, and drug status, making it more challenging to manage acute kidney injury (AKI). Low sensitivity and specificity of biomarkers are expected to hamper the Asia Pacific renal biomarkers market. For example, some renal biomarkers, such as L-18, are more specific but not particularly sensitive, whereas others, such as osteopontin, are empathetic but not specific. China is the world's industrial powerhouse with the leading raw material providers. The broad market breakdown induced by COVID-19 also affects the market's growth due to manufacturing closures, supply chain hurdles, and the economic crisis. 

This research report on the Asia Pacific Renal Biomarkers Market has been segmented and sub-segmented into the following categories.

By Diagnostic Technique:

• Chemiluminescent Enzyme Immunoassay
• Colorimetric Assay
• Enzyme-Linked Immunosorbent Assay
• Liquid Chromatography-Mass Spectrometry
• Particle-Enhanced Turbidimetric Immunoassay

By Type:

• Up-Regulated Proteins
• Interleukin 18
• Kidney injury molecule 1
• Neutrophil gelatinase-associated lipocalin
• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, renal cancer can be detected early and treated before it progresses. The primary factors driving the Asia Pacific renal biomarkers market are the increased incidence of illnesses, a high elderly population, and the rising prevalence of numerous comorbidities. 

The China renal biomarkers market and India renal biomarkers market have the most significant share globally over the projection period in the Asia Pacific region.

In addition, introducing new products and assays throughout the predicted period will boost the industry's growth. Almost every pharmaceutical business has launched a molecular biomarker program, either through alliances or other means. According to the World Bank Group, China's healthcare spending reached 5.8% of GDP in 2016 and is predicted to quadruple by 2022. 

The renal biomarkers market is driven by solid expansion in healthcare spending and rising worldwide per capita income. In addition, the renal biomarkers market is expected to grow as healthcare infrastructure improves and government reimbursement programs are implemented.

KEY MARKET PLAYERS

Top Companies dominating the Asia Pacific Renal Biomarkers Market Profiled in the Report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.,